Myasthenia Gravis: Pathogenesis and Immunotherapy
|
|
- Dwight Dawson
- 5 years ago
- Views:
Transcription
1 REVIEW ARTICLE Myasthenia Gravis: Pathogenesis and Immunotherapy Christiane Schneider-Gold, Klaus V. Toyka SUMMARY Introduction: In autoimmune myasthenia gravis (MG) autoantibodies directed against the postsynaptic nicotinic acetylcholine receptor (ACh-R) lead to a reduction of the number of available ACh-R thereby impeding neuromuscular transmission. Methods: Selective review of literature and available guidelines relating to the pathogenesis and treatment of myasthenia gravis. Results: Disorders of the thymus play a crucial role in the pathogenesis of ACh-R antibody positive MG, particularly by generating Ach-R specific autoreactive T cells. The main clinical symptoms are skeletal/striated muscle weakness and exercise-induced fatigue involving extraocular, facial and bulbar muscles (generalized MG). In the purely ocular form of MG only extraocular muscles are involved. Treatment of MG includes the application of acetylcholineesterase inhibitors and immunosuppressive drugs including glucocorticosteroids, azathioprine, and others most of which are off-label. Myasthenic crisis is characterized by most severe weakness, swallowing difficulties and respiratory failure, therefore requiring intensive care therapy. Dtsch Arztebl 2007; 104(7): A Key words: myasthenia gravis, autoimmune disease, neuromuscular disease, treatment, immunotherapy, acetyl-choline T he key manifestation of myasthenia gravis (MG) is fluctuating muscle weakness which typically increases during effort Myasthenia gravis is a chronic autoimmune disease, sub-classified according to the Osserman und Genkins classification (2), and, more recently, that of the MGFA (Myasthenia Gravis Foundation of America) - Task-Force (3) (table 1). According to these criteria, ocular MG is characterized by fluctuating unilateral or bilateral ptosis, and, frequently, double vision, both deteriorating during the day. Generalized MG with additional involvement of arm, leg and trunk muscles as well as respiratory, facial and bulbar muscles is divided into different sub-categories dependent on disease severity. Muscle atrophy is rarely present and only in the late stages of severe, and insufficiently treated MG (1, 3). Generalized forms without typical ocular symptoms pose a particular diagnostic challenge. The prevalence of MG is between 25 and 100 per million population (1). MG presents most commonly between the ages of 20 to 40 and 60 to 70 (female to male ratio 3:2) (1). Clinical examination The examination of the extra ocular musculature includes: the eyelid fatigue test while looking upwards for one minute, with recovery after brief maximal eyelid closure (4) the diplopia stress test (looking sideways for at least one minute) the red glass test (red glass in front of the right and light source in front of the left eye, to distinguish double images) the eliciting of the so-called Cogan sign, transient jerks of the eyelid immediately after looking quickly downwards and then upwards (4) and weakness of the periocular musculature (eyelash sign). In the modified Besinger and Toyka myasthenia score (5), the weakness and fatigue of the preferentially affected proximal muscle groups, the vital capacity (via spirometry) and Abteilung Neurologie, Georg-August Universität Göttingen, (PD Dr. med. Schneider-Gold); Neurologische Klinik und Poliklinik der Julius-Maximilians-Universität Würzburg, (Prof. Dr. med. Toyka) Dtsch Arztebl 2007; 104(7): A
2 TABLE 1 Osserman und Genkins (2) classification of myasthenia gravis, modified by the MGFA/Task Force (3) Class Clinical form(s) Symptoms I*/MGFA I Ocular form Ptosis, diplopia II a*/mgfa II Mild generalized form Mild generalized weakness II b*/mgfa IIb Faciopharyngeal form IIa + bulbar weakness III* Severe acute generalized form Acute severe general weakness + bulbar symptoms + respiratory insufficiency MGFA III Medium severity generalized form Medium severity generalized weakness with MGFA IIIa involvement of the extremities/trunk muscles > faciopharyngeal musculature MGFA IIIb Faciopharyngeal/respiratory musculature > extremities/ trunk musculature IV* Severe chronic generalized form Severe, often progressive generalized weakness MGFA IV Severe generalized form MGFA IVa MGFA IVb Extremities/trunk musculature > faciopharyngeal musculature Faciopharyngeal/respiratory musculature > extremities/ trunk musculature V* Myasthenia with severe residual deficits Severe chronic form with muscle atrophy MGFA V Severe MG requiring intubation MGFA, Myasthenia Gravis Foundation Association; the entries marked* refer to the Os-serman and Genkins classification the spontaneous ocular and faciopharyngeal symptoms and their degree of worsening with effort are presented in a summary score (table 2). Differential diagnosis of myasthenia gravis Among the differential diagnoses are mitochondrial myopathy, botulism from food poisoning, myositis, congenital myasthenic syndrome and Lambert Eaton myasthenic syndrome (LEMS). Lambert Eaton myasthenic syndrome is a neuromuscular disorder of presynaptic neurotransmission mediated by auto-antibodies against voltage-gated calcium channels, characterized by muscular weakness and autonomic disorders such as dry mouth, hyposalivation and impotence (3). Its prevalence is around or below 1 to 2 per TABLE 2 Myasthenia score modified according to Besinger und Toyka (5)* 1 No weakness (0) Mild weakness (1) Moderate weakness (2) Marked weakness (3) Arm outstretched > 180 Sec Sec Sec. < 10 Sec. time* 2 Leg outstretched > 45 Sec Sec Sec. < 5 Sec. time* 3 Head outstretched > 90 Sec Sec Sec. < 5 Sec. time* 4 Vital capacity* 5 > 4,0 L (m) 2,5 4 L (m) 1,5 2,5 L (m) < 1,5 L (m) > 3,0 L (w) 2,0 3,0 L (w) 1,2 2 L (w) < 1,2 L (w) FEV1 > 90 % % % < 40 % Chewing/swallowing Normal Fatiguing Soft foods only Gastrostomy (with solid food) needed Facial expression Normal Lid closure weak Incomplete lid closing No facial expression Diplopia > 60 Sec Sec. > 0 10 Sec. Spontaneous diplopia Ptosis > 60 Sec Sec. > 0 10 Sec. Spontaneous ptosis * 1 This original score has been adapted and extended for clinical trials by the MGFA * 2 Dominant arm, outstretched horizontal during sitting; in semi prone, severely ill patients, lift arm by about (the outstretched times are only approximate measures) * 3 Supine, dominant leg, lifted 45 * 4 Supine, head lifted 45 * 5 Vital capacity measured while seated; m, men, w, women; FEV1 = forced expiratory volume at one second Dtsch Arztebl 2007; 104(7): A
3 Pathogenesis of myasthenia gravis MG is a prototypical antibody-mediated, T-helper cell dependent autoimmune disease (6, 7, 8, 9, 10). The majority of MG patients have antibodies directed against the alpha subunit of the nicotinergic acetylcholine receptor (Ach-R) of skeletal muscle (6), which lead to loss of receptors and destruction of the postsynaptic membrane (6). Blocking antibodies bind at or in the immediate vicinity of the acetylcholine binding sites and are usually not detected on standard laboratory testing (see below) (9). Autoantibodies directed against the acetylcholine receptor (Ach-R) are produced in the thymus and in the lymphatic system by ACh-R-specific auto-reactive T and B lymphocytes which are generated during thymus maturation (10). In the healthy individual, these autoimmune T-cells are eliminated or adequately controlled by regulatory T-cells. The primary triggering event is as poorly understood as in other autoimmune diseases. Ach-R antibodies are detected in 80% to 90% of patients with generalized MG and in about 50% of patients Figure: CT scan of a thorax showing a thymoma in the anterior mediastinal region which was confirmed after surgical removal (arrow). with ocular MG. In up to 40% of patients formerly classified as suffering from sero-negative MG, specific antibodies against muscle-specific tyrosine kinase (MuSK) can be identified (11). In MuSK positive MG bulbopharyngeal and respiratory muscles are preferentially affected (11). This form of MG accounts for around two to five percent of acetyl-choline receptor (Ach-R) antibody negative cases who have generalized myastasis. In around five percent of patients with generalized MG no specific antibodies can be found, meaning that additional target antigens can be assumed to exist. In around 70% of acetyl-choline receptor (Ach-R) antibody positive patients under 40, the thymus shows the histological picture of thymitis with lymphofollicular hyperplasia. In MuSK-antibody-associated myasthenia, the thymus is for the most part morphologically normal (12). Patients over 40 mostly have age-related thymic atrophy (1). Thymomas (figure) or thymic carcinomas (13) are found in five to fifteen percent of patients (paraneoplastic MG). Mature, potentially auto-reactive T-cells are produced in the non-neoplastic area of these tumors; the maturation and export of regulatory T-cells is reduced (14). Additional investigations Electrophysiology The exhaustion of neuromuscular transmission due to a reduced number of functional postsynaptic acetylcholine receptors can be demonstrated electrophysiologically by means of supramaximal electrical repetitive 3Hz stimulation (serial nerve stimulation) of, for example, the accessory nerve, or the facial nerve, with measurement of the myoelectric response in the corresponding muscles. A positive decrement (reduction in the amplitude/area by more than 15%/10%) is found in up to 80% of patients with generalized MG and in less than 50% of patients with the ocular form (15). Pharmacological testing In the Tensilon test, 2 ml of edrophonium chloride are given initially in the adult patient intravenously (10 mg edrophonium chloride dissolved in 9 ml physiological saline solution). After a minute, if there is no response and there are no side effects, a further 8 ml are given, Dtsch Arztebl 2007; 104(7): A
4 BOX 1 Stepwise approach to the pharmacological treatment of myasthenia gravis 1. Acetylcholin esterase inhibitors (basic maintenance treatment) Pyridostigmine 60 mg 4 hourly, optional mg retard (time span) at bedtime * 1 2. Glucocorticosteroids mg methylprednisolone (or prednisone/prednisolone) p/o (gradual increase or start with maintenance dose, with gradual reduction on remission). Caution: transient worsening is possible 3. Immunosuppressive long term therapy Azathioprine mg/day (2 3 mg/kg) * 2 Cyclosporin A mg/day * 3 Medication for non- or poor responders Mycophenolat mofetil mg/day * 4 Methotrexate 7.5 mg/week * 4 Cyclophosphamide 500 mg/m2 IV every 4 12 weeks or 1 2 mg/kg/day p/o * 4,* 5 Tacrolimus mg/day; reserved for intractable cases * 6 Rituximab (Mabthera) * 6 * 1 Retard preparation only useful with definite over night or morning symptoms * 2 Administration in 3 daily doses following meals is better tolerated than 1 2 doses; prior test dose of 1 50 mg * 3 Only with regular monitoring of fasting plasma levels, class 1-evidence based, but not yet licensed for MG * 4 Unlicensed but successful in a number of case reports * 5 Only in severe refractory disease; higher doses required for "immune ablation" with rescue medication off-label * 6 Very limited experience off label with atropine sulphate held ready for administration as an antagonist, should muscarinic side effects (asthma attack, bradycardia) occur. The Tensilon test can be combined with the serial nerve stimulation test, used before and afterwards, in diagnostically difficult cases (15). In high risk patients and in outpatients, a test with oral pyridostigmine should first be carried out, with subsequent testing after 60 minutes, and a clearly positive response may be sufficient to make the diagnosis. Laboratory investigations The analysis of patient serum for pathologically raised titers of acetylcholine receptor antibodies using an immune precipitation test (acetylcholine receptor extracts from human amputated muscle) is the most specific tool in the diagnosis of MG (6). Seronegative patients should be tested for antibodies against MuSK. Imaging investigations Imaging of the thorax with CT or MRI to investigate the thymus is mandatory in all new cases of MG, and should be repeated at intervals of one to two years, even where the initial investigation was normal, to exclude incipient thymoma. Scintigraphy using indium-111- DTPA-D-phe-octreotide can be helpful in imaging the extent of growth of a thymoma by means of the somatostatin receptors expressed on the surface, even where there is considerable scarring following surgery (16). Treatment MG is one of the best treatable autoimmune diseases. The cornerstones of treatment are thymectomy, acetylcholinesterase inhibitors, immunosuppressive drugs and plasmapheresis (1, 3). The aim of treatment is remission with the best possible quality of life. In autoimmune MG, the use of glucocorticoids, cyclosporin A, combination therapy with azathioprine and glucocorticoids, as well as plasmapheresis and immunoglobulins, is supported by studies designed to provide class 1 evidence (17, 18, 19, 20). However, some of these studies fail to reach this level, due for example to problems with recruitment (box 1). Only class 2 Dtsch Arztebl 2007; 104(7): A
5 evidence exists for second line immunosuppressive treatments such as tacrolimus, methotrexate and cyclophosphamide, as well as for MTX and cyclosporin A, and for these there is no formal licence for this indication in many countries. The effect of thymectomy on the progression on MG has only been investigated by evidence class 2 studies (21). A metaanalysis of available class 2 evidence studies on thymectomy in myasthenia gravis (21) suggests that complete thymectomy in patients under 45 can improve prognosis. The upper age limit for thymectomy is at around age 60. In purely ocular disease, thymectomy is not indicated. Where there is suspicion of a thymoma, radical surgery is essential to clarify the histological picture. Invasive or metastasizing cortical thymomas and well differentiated thymus carcinomas can additionally be treated with radiotherapy and chemotherapy, which is thought to improve prognosis. Pyridostigmine, given in a dose of 60 mg three to seven times daily has proved helpful as oral, symptomatic treatment. Its effect can be demonstrated electrophysiologically (6). Pyridostigmine inhibits the hydrolytic cleavage of acetylcholine (15) and thereby improves neuromuscular transmission. Symptomatic treatment with pyridostigmine is, however, seldom sufficient in itself. Initial immunosuppressive treatment begins with glucocorticoids in rising doses (30 to 100 mg p/o) or with an intermediate dose of 60 mg/day. Due to a reinforcement of the acetylcholine receptor ion channel dysfunction, a transient worsening of symptoms may occur between two and twelve days after treatment has been given. Because of their toxicity, steroids as immunosuppressive monotherapy are only used in low doses (10 30 mg/day) in ocular myasthenia, and are otherwise tailed down once a significant improvement has been achieved. The effect of glucocorticosteroids is supported by class 1 evidence, although the class 1 criteria are only partially fulfilled in the individual studies (17). In order to limit the use of steroids, immunosuppressive drug maintenance therapy should be given in generalized MG from the acute phase, with azathioprine (AZA) in a dosage of 50 mg b.i.d. or t.i.d. (total daily dose 2.5 to 3 mg/kg) is the treatment of first choice (1) (box 1). From a practical point of view, a single test dose of 50 mg is advisable before commencing maintenance therapy, to exclude occasional severe idiosyncratic reactions (fewer than 0.5% of patients). The biologically active form (6-mercaptopurine) inhibits T and B lymphocyte proliferation, thereby reducing antibody production. The therapeutic efficacy of AZA in combination with corticosteroids is supported by a single study of class 1 level evidence (19). During treatment with AZA the total leucocyte count should not drop down to less than at least 3.500/µL and the absolute lymphocyte count should be maintained between 500 and 900/µL. In thiopurine methyl transferase deficiency or in simultaneous treatment with allopurinol for gout, AZA is not, or is incompletely, broken down, so that a normal dose can lead to dangerous leucopenia. In these cases 25% to 50% of the normal dose should be used. BOX 2 Management of myasthenic crisis 1. Acetylcholine esterase inhibitors Physostigmine 8 24 mg/day IV (initially always with atropine sulphate) 2. Glucocorticosteroids Up to 500 mg methylprednisolone IV or 100 mg p/o (with gradual reduction on remission) 3. Plasma separation techniques Plasmapheresis (non-selective) or additional immune adsorption (semi-selective), Exchange of 1 2 plasma volumes 2 3 weekly for 2 weeks 4. Immunoglobulins IV (only for specific indications) 0.4 g/kg on 5 consecutive days 5. Immunosuppressive long term therapy (see above) Begin as soon as possible or continue at a higher dose/combination Dtsch Arztebl 2007; 104(7): A
6 The measurement of thiopurine methyl transferase activity is advisable in early and marked AZA-associated leucopenia. Where enzyme activity is lacking, AZA is contraindicated. Treatment with AZA should be continued for at least two to three years, and be reduced by 25 mg every three months where there is remission and the acetylcholine receptor antibody titers are stable. If AZA is discontinued too abruptly or too soon, relapses can occur (22). Where there is intolerance or inadequate effect, another immunosuppressive drug should be used (box 1). Treatment must be under continual medical review, as must any chemotherapy. Cyclosporin A (CYC A) works by inhibiting calcineurin synthetase, thereby inhibiting the synthesis of cytokines and the activation of T lymphocytes (1). CYC A is given at a dose of 2 50 mg to mg orally (2 to 5 mg/kg). Its efficacy is supported by evidence class 1 studies (18). A fasting plasma level of 70 to 100 µg/ml after 12 hours should be aimed for, in myasthenia gravis. Significant side effects include arterial hypertension, nephropathy and neurotoxicity (encephalopathy). Around 5% of patients are unable to tolerate AZA or CYC A, or respond inadequately. In these cases, mycophenolat mofetil may be used for long term immunosuppression. Mycophenolat mofetil (2 500 to mg/day) is first converted in the body to mycophenolic acid, which selectively, non-competitively and reversibly inhibits inosine monophosphate dehydrogenase and hence inhibits de novo synthesis of guanosine nucleotide synthesis (23). Methotrexate is used on rare occasions (7.5 to 15 mg/week [1]). It inhibits lymphocyte proliferation via inhibiting folate synthesis. Significant side effects include pulmonary fibrosis and bone marrow suppression. Cyclophosphamide is a fallback treatment for the most intractable cases (1). It is cytotoxic and immunosuppressive, and is given either intravenously (500 mg/m 2 of body surface area (SA), at intervals of 4 to 12 weeks, or, less commonly, orally (1 to 2 mg/kg BW/day). A maximal cumulative lifetime dose of 45 g should not be exceeded due to cumulative toxicity. A high dose therapy at 50 mg/kg BW and subsequent rescue therapy with granulocyte stimulating factor (G-CSF) (so-called immune ablation) should remain an option for the most intractable cases (24). "Off label" use With the exception of AZA, none of the above long term immunosuppressive treatments is licensed for use in MG in Germany and in some other European countries. Hence, these may only be used "off label" where AZA is not tolerated. The cost of such treatment is only reimbursable under health insurance arrangements by prior permission. Approaches under investigation Among newer treatment approaches is rituximab, an antibody against a surface antigen expressed by B-cell precursors (CD 20), which may be used off label at a dose of 375 mg/m 2 SA in refractory cases of MG. Tacrolimus, like CYC A, blocks calcineurin activity and hence inhibits T lymphocyte proliferation. Although observational studies have shown benefit from tacrolimus in MG (23), its use is not currently established in Germany. Treatment of myasthenic crisis Severe generalized illness, infections and operations can precipitate myasthenic crisis with acute generalized weakness, swallowing difficulties and respiratory failure (1, 25). Myasthenic crises are rare nowadays, and occur primarily in the first two years of disease onset. Where the forced vital capacity falls below 1.2 l (15 ml/kg body weight) or where oxygen is required, artificial ventilation is indicated (1, 25). The intensive care management of myasthenic crisis includes first a switch from pyridostigmine to physostigmine as an i.v. drip or in the perfusor, in combination with subcutaneous atropine, high dose intravenous glucocorticoids and plasmapheresis (1, 3, box 2). In general, one to two times the plasma volume is exchanged three times weekly over a two week period. Only where this is contraindicated (sepsis, poor venous access, age over 70) would we recommend intravenous immunoglobulin G as a first line treatment. This is only marginally less effective than plasmapheresis, given in a dose of 0.4 g/kg in Dtsch Arztebl 2007; 104(7): A
7 TABLE 3 Medications relatively contraindicated in MG * 1 Substance group Analgesics Antibiotics Antidepressants Rheumatological agents Beta-blockers Calcium antagonists Magnesium Examples Morphine, flupirtine Aminoglycosides, macrolides, ketolides, gyrase inhibitors, sulphonamides, tetracyclines, penicillins (high doses) Tricyclics D penicillamine, chloroquine Pindolol, propranolol, timolol Verapamil, diltiazem, nifedipine High dose magnesium, e. g. in tocolysis Muscle relaxants Curare derivatives (max % of the normal dose), succinyl choline * 1 These restrictions apply for patients with clinically visible signs, despite treatment with cholinesterase inhibitors; they may be used otherwise with observation during first treatment. MG, myasthenia gravis five consecutive days (class 1 evidence level 4) (box 2) (20). The efficacy of intravenous immunoglobulins rests in part on the neutralization of circulating antibodies, the inhibition of B-cell activation and complement binding, the blockade of Fc receptors, and the modulation of T-cell function (1). With these measures, myasthenic crisis can usually be brought under rapid control. Adequate ongoing immunosuppression should be commenced or increased, at an early stage. Total mortality in myasthenic crisis, of which elderly patients and those with comorbidity are at greatest risk, has fallen to under 5%, thanks to efficient short and long term treatments and improvements in intensive care (1, 25). These improvements also permit successful management of even complicated cases. Management during anaesthesia, surgery and pregnancy Muscle relaxants during anaesthesia should either be withheld, or given only in the form of a tenth of the usual dose, in the form of a medium acting non-depolarizing agent such as atracurium. A prolonged postoperative ventilation requirement is to be expected. For local anaesthesia, an amide type agent should preferably be used, such as lidocaine (1). It is generally not needed to discontinue long term immune suppressants preoperatively. Pregnant women with MG should deliver in a center experienced in the management of this condition, and with neonatal intensive care facilities available. This is important because, regardless of the severity of maternal disease, 10% of neonates will suffer transient myasthenia (1). The maternal disease can also worsen. Medications which can worsen myasthenia gravis include: D penicillamine, antibiotics, antidepressants, beta-blockers, calcium antagonists and magnesium (table 3). Acknowledgement The electronmicrograph (front cover) of a mouse neuromuscular junction was provided by Dr. Archinto P. Anzil. Conflict of Interest Statement Prof. Dr. med. Klaus Toyka has received consultancy fees from pharmaceutical companies involved in the area of immune therapy and has been paid as a reviewer in the licensing of Imurek (azathioprine) in myasthenia. In addition, he has advised companies on therapeutic studies of immunoglobulins in myasthenia, pro bono; he has authored and co-authored treatment guidelines for pharmaceutical companies and professional bodies, for which costs of printing were in part covered by educational grants from pharmaceutical companies. PD Dr. med. Christiane Schneider-Gold has received remuneration for giving lectures for the company Temmler Pharma, which manufactures the drug Kalymin. Manuscript received on 22 June 2006, final version accepted on 26 August Translated from the original German by Dr. Sandra Goldbeck-Wood, and edited by the authors. Dtsch Arztebl 2007; 104(7): A
8 REFERENCES 1. Hohlfeld R, Melms A, Schneider C, Toyka KV, Drachman DB: Therapy of myasthenia gravis and myasthenic syndromes. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (eds.): Neurological disorders course and treatment. Amsterdam: Elsevier 2003: Osserman KE, Genkins G: Studies in myasthenia gravis: review of a twenty-year experience in over patients. Mt Sinai J Med 1971; 38: Melms A, Gold R, Hohlfeld R, Schalke B, Schumm F, Toyka KV: Myasthenie. In: Diener HC, Putzki N, Berlit P (Hrsg.): Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart; Thieme Verlag 2005; Toyka KV: Ptosis in myasthenia gravis: extended fatigue and recovery bedside test. Neurology 2006; 67: Besinger UA, Toyka KV, Homberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A: Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983; 33: Lindstrom J: An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol 1977; 7: Toyka KV, Drachman DB, PestronkA, Kao I: Myasthenia gravis. Passive transfer from man to mouse. Science 1975; 190: Heininger K, Hartung HP, Toyka KV, Gaczkowski A, Borberg H: Therapeutic plasma exchange in myasthenia gravis: semiselective adsorption of Anti-AChR autoantibodies with tryptophane-linked polyvinylalcohol gels. Ann N Y Acad Sci 1987; 505: Bufler J, Pitz R, Czep M, Wick M, Franke C: Purified IgG from seropositive and seronegative patients with myasthenia gravis reversibly block currents through nicotinic acetylcholine receptor channels. Ann Neurol 1998; 43: Hohlfeld R, Wekerle H: The immunopathogenesis of myasthenia gravis. In: Engel AG (Hrsg.): Myasthenia gravis and myasthenic syndromes. Oxford University Press, Oxford, 1999: Vincent A, Bowen J, Newsom-Davis J, McConville J: Seronegative generalised myasthenia gravis: clinical features, antibodies and their targets. Lancet Neurology 2003; 2: Leite MI, Strobel P, Jones M et al.: Fewer thymic changes in MuSK-positive than in MuSK-negative MG. Ann Neurol 2005; 57: Ströbel P, Marx A, Zettl A, Müller-Hermelink HK: Thymoma and thymic carcinoma: an update of the WHO Classification Surg Today 2005; 35: Ströbel P, Rosenwald A, Beyersdorf N et al.: Selective loss of regulatory T-cells in thymomas. Ann Neurol 2004; 56: Schneider C, Reiners K: Elektrophysiologische Diagnostik neuromuskulärer Übertragungsstörungen. Klin Neurophysiol 2000; 31: Marienhagen J, Schalke B, Aebert H, Held P, Eilles C, Bogdahn U: Somatostatin receptor scintigraphy in thymoma imgaing method and clinical application. Pathol Res Pract 1999; 195: Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR:Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005; CD Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K: A clinical therapeutic trial of ciclosporine in myasthenia gravis. Ann N Y Acad Sci 1993; 681: Palace J, Newsom-Davis J, Lecky B: A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50: Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C: Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurology 1997; 41: Gronseth GS, Barohn RJ: Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidencebased review). Neurology 2000; 55: Michels M, Hohlfeld R, Hartung HP, Heininger K, Besinger UA, Toyka KV: Myasthenia gravis: discontinuation of longterm azathioprine. Ann Neurol 1988; 24: Schneider-Gold C, Hartung HP, Gold R: Mycophenolate mofetil and tacrolimus: new therapeutic options in the therapy of neuroimmunological diseases. Muscle Nerve 2006; 34: Drachman DB, Jones RJ, Brodsky RA: Treatment of refractory myasthenia gravis: Rebooting with high dose cyclophosphamide. Ann Neurol 2003; 53: Thomas CE, Mayer SA, Gungor Y: Myasthenic crisis: clinical features, mortality, complications and risk factors for prolonged intubation. Neurology 1997; 48: Corresponing author PD Dr. med. Christiane Schneider-Gold Abteilung Neurologie der Georg-August-Universität Göttingen Robert-Koch Str Göttingen, Germany c.schneider-gold@med.uni-goettingen.de Dtsch Arztebl 2007; 104(7): A
Myasthenia gravis. David Hilton-Jones Oxford Neuromuscular Centre
Myasthenia gravis David Hilton-Jones Oxford Neuromuscular Centre SWIM, Taunton, 2018 Myasthenia gravis Autoimmune disease Nature of Role of thymus Myasthenia gravis Autoimmune disease Nature of Role of
More informationMyasthenia: Is Medical Therapy in the Grave? Katy Marino, PGY-5
Myasthenia: Is Medical Therapy in the Grave? Katy Marino, PGY-5 Disclosures Outline History of Thymus Anatomy of Thymus Pathophysiology of Myasthenia Gravis Medical Management of Myasthenia Gravis Surgical
More informationMyasthenia Gravis. Mike Gilchrist 10/30/06
Myasthenia Gravis Mike Gilchrist 10/30/06 Overview Background Pathogenesis Clinical Manifestations Diagnosis Treatment Associated Conditions Background Severe muscle disease Most common disorder of neuromuscular
More informationCLINICAL PRESENTATION
MYASTHENIA GRAVIS INTRODUCTION Most common primary disorder of neuromuscular transmission Usually due to acquired immunological abnormality Also due to genetic abnormalities at neuromuscular junction.
More informationProgress in the treatment of myasthenia gravis
Review Progress in the treatment of myasthenia gravis Ralf Gold, Reinhard Hohlfeld and Klaus V. Toyka Abstract: Substantial therapeutic progress has been made in myasthenia gravis (MG) even before the
More informationSurgery for the treatment of myasthenia gravis. Tim Batchelor Department of Thoracic Surgery Bristol Royal Infirmary
Surgery for the treatment of myasthenia gravis Tim Batchelor Department of Thoracic Surgery Bristol Royal Infirmary The role of thymectomy It is of considerable interest to find a relationship between
More informationMyasthenia Gravis What is Myasthenia Gravis? Who is at risk of developing MG? Is MG hereditary? What are the symptoms of MG? What causes MG?
Myasthenia Gravis What is Myasthenia Gravis? Myasthenia Gravis (MG) is a chronic, autoimmune disease that causes muscle weakness and excessive muscle fatigue. It is uncommon, affecting about 15 in every
More informationMYASTHENIA GRAVIS. Mr. D.Raju, M.pharm, Lecturer
MYASTHENIA GRAVIS Mr. D.Raju, M.pharm, Lecturer OUTLINE Background Anatomy Pathophysiology Clinical Presentation Treatment BACKGROUND Acquired autoimmune disorder Clinically characterized by: Weakness
More informationMyasthenia gravis. Page 1 of 7
Myasthenia gravis What is myasthenia gravis? Myasthenia gravis (sometimes abbreviated to MG) is a chronic, autoimmune condition that causes muscle weakness and excessive muscle fatigue. It is rare, affecting
More informationThe role of plasmapheresis in Myasthenia Gravis. Ri 陳文科
The role of plasmapheresis in Myasthenia Gravis Ri 陳文科 Myaasthenia Gravis S/S: 2/3 initial symptoms: Ocular motor disturbances, ptosis or diplopia. 1/6:Oropharyngeal muscle weakness 1/10: limb weakness
More informationRandomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine - August 11, 2016
Randomized Trial of Thymectomy in Myasthenia Gravis New England Journal of Medicine - August 11, 2016 Disclosures None At all. Example Case 38 year-old female with no pertinent PMH who presents with a
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationPeripheral neuropathies, neuromuscular junction disorders, & CNS myelin diseases
Peripheral neuropathies, neuromuscular junction disorders, & CNS myelin diseases Peripheral neuropathies according to which part affected Axonal Demyelinating with axonal sparing Many times: mixed features
More informationMyasthenia Gravis. Stephen L. McKernan, DO. brief report INTRODUCTION DIAGNOSIS KEYWORDS:
38 Osteopathic Family Physician Volume 11, No. 1 January/February, 2019 Osteopathic Family Physician (2019) 38-42 brief report Stephen L. McKernan, DO Sam Houston State University Proposed College of Osteopathic
More informationStanley Iyadurai, PhD MD. Assistant Professor of Neurology/Neuromuscular Medicine Nationwide Children s Hospital Myology Course 2015
1 Stanley Iyadurai, PhD MD Assistant Professor of Neurology/Neuromuscular Medicine Nationwide Children s Hospital Myology Course 2015 Motor unit motor neuron, its axon, and nerve terminals, and muscle
More informationImmunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration
637046TAN0010.1177/1756285616637046Therapeutic Advances in Neurological DisordersC. Schneider-Gold et al. research-article2016 Therapeutic Advances in Neurological Disorders Original Research Immunoadsorption
More informationReview Article Myasthenia Gravis: A Review of Available Treatment Approaches
SAGE-Hindawi Access to Research Autoimmune Diseases Volume 2011, Article ID 847393, 6 pages doi:10.4061/2011/847393 Review Article Myasthenia Gravis: A Review of Available Treatment Approaches Nils Erik
More informationME Farrugia Consultant Neurologist, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
CME doi:10.4997/jrcpe.2011.111 2011 Royal College of Physicians of Edinburgh Myasthenic syndromes Consultant Neurologist, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK ABSTRACT
More informationCSCN Hot Topics What s New in the Treatment of Myasthenia Gravis? Dr. Fraser Moore CNSF Congress Victoria, BC Tuesday June 20 th 2017
Introduction CSCN Hot Topics What s New in the Treatment of Myasthenia Gravis? Dr. Fraser Moore CNSF Congress Victoria, BC Tuesday June 20 th 2017 The overall goal of this session is to look at recent
More informationINTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES
International Journal of Institutional Pharmacy and Life Sciences 5(5): September-October 2015 INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES Pharmaceutical Sciences Review Article!!!
More informationEDUCATIONAL COMMENTARY NEUROLOGIC AUTOIMMUNE DISEASES
EDUCATIONAL COMMENTARY NEUROLOGIC AUTOIMMUNE DISEASES Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits,
More informationClinical predictors of steroid-induced exacerbation in myasthenia gravis
Journal of Clinical Neuroscience 13 (2006) 1006 1010 Clinical study Clinical predictors of steroid-induced exacerbation in myasthenia gravis Jong Seok Bae a, Seok Min Go a, Byoung Joon Kim b, * a Department
More informationDiseases of Muscle and Neuromuscular Junction
Diseases of Muscle and Neuromuscular Junction Diseases of Muscle and Neuromuscular Junction Neuromuscular Junction Muscle Myastenia Gravis Eaton-Lambert Syndrome Toxic Infllammatory Denervation Atrophy
More informationGlobal Myasthenia Gravis Market: Size, Trends & Forecasts ( ) August 2017
Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021) August 2017 Global Myasthenia Gravis Market Scope of the Report The report titled Global Myasthenia Gravis Market: Size, Trends & Forecasts
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
SOLIRIS (eculizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationComparison of IVIg and PLEX in patients with myasthenia gravis
Comparison of IVIg and PLEX in patients with myasthenia gravis D. Barth, MD M. Nabavi Nouri, MD E. Ng, MD P. Nwe, MD V. Bril, MD Address correspondence and reprint requests to Dr. Vera Bril, 5EC-309, Toronto
More informationANAESTHESIA AND MYASTHENIA GRAVIS ANAESTHESIA TUTORIAL OF THE WEEK TH DECEMBER 2008
ANAESTHESIA AND MYASTHENIA GRAVIS ANAESTHESIA TUTORIAL OF THE WEEK 122 15 TH DECEMBER 2008 Dr Arnab Banerjee Hospital Luton & Dunstable Hospital NHS Trust Correspondence to abanerjeeuk@doctors.org.uk INTRODUCTION
More informationLA TIMECTOMIA ROBOTICA
LA TIMECTOMIA ROBOTICA Prof. Giuseppe Marulli UOC Chirurgia Toracica Università di Padova . The thymus presents a challenge to the surgeon not only as a structure that may be origin of benign and malignant
More informationAryendu Kumar Saini et al. Int. Res. J. Pharm. 2017, 8 (3) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article A REVIEW ON MYASTHENIA GRAVIS Aryendu Kumar Saini 1 *, Aditya Gupta 2, Shubham Singh 3, Hemendra Pati Tripathi
More informationFacts about Myasthenia Gravis
The information in this fact sheet was adapted by the MDNSW (06/06) from the MDA USA fact sheet (updated 11/05) with their kind permission. Facts about Myasthenia Gravis Myasthenia Gravis (MG), Lambert-Eaton
More information8/13/2018. Update in Myasthenia Gravis. Ikjae Lee, MD. None
Update in Myasthenia Gravis Ikjae Lee, MD Assistant professor, UAB Neuromuscular Medicine 2018 Alabama Academy of Neurology Annual Meeting Disclosure None Page 2 Contents Overview of Myasthenia Gravis
More informationMyasthenia gravis. THE PET HEALTH LIBRARY By Wendy C. Brooks, DVM, DipABVP Educational Director, VeterinaryPartner.com
THE PET HEALTH LIBRARY By Wendy C. Brooks, DVM, DipABVP Educational Director, VeterinaryPartner.com Myasthenia gravis What You Need to Know to Understand this Disease Myasthenia gravis is a disease that
More informationOcular myasthenia gravis: response to long term immunosuppressive treatment
156 16ournal of Neurology, Neurosurgery, and Psychiatry 1997;62:156-162 Department of Neurology N Sommer B Sigg A Melms M Weller K Schepelmann J Dichgans Department of Ophthalmology, Eberhard-Karls- University
More informationSteroids and Immunosuppressant Drugs in Myasthenia Gravis
Stránka č. 1 z 14 www.medscape.com To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/579054 Steroids and Immunosuppressant
More informationPage 1 of 6 Title Authored By Course No Contact Hour 1 An Overview of Myasthenia Gravis Ray Lengel RN, FNP, MS MG2061208 Purpose The goal of this course is to provide an understanding about myasthenia
More informationMyasthenia gravis. What You Need to Know to Understand this Disease
Myasthenia gravis What You Need to Know to Understand this Disease Myasthenia gravis is a disease that interrupts the way nerves communicate with muscles. In order to understand this disease, you must
More informationMyasthenia Gravis. Abstract. Overview. Daniel B. Drachman, MD 1
419 Daniel B. Drachman, MD 1 1 Department of Neurology & Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland Semin Neurol 2016;36:419 424. Address for correspondence Daniel B. Drachman,
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Soliris GENERIC NAME Eculizumab MANUFACTURER Alexion Pharmaceuticals, Inc. DATE OF APPROVAL October 23, 2017 PRODUCT LAUNCH DATE Currently commercially available REVIEW TYPE Review type 1 (RT1):
More informationIs the Stimulation Frequency of the Repetitive Nerve Stimulation Test that You Choose Appropriate?
186 Is the Stimulation Frequency of the Repetitive Nerve Stimulation Test that You Choose Appropriate? Yuan-Ting Sun and Thy-Sheng Lin Abstract- The repetitive nerve stimulation test (RNST) has been a
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20412 holds various files of this Leiden University dissertation. Author: Niks, E.H. Title: Myasthenia gravis with antibodies to muscle-specific kinase
More informationA CLINICAL SURVEY IN
Med. J. Malaysia Vol. 35 No. 2 December 1980. MYASTHENIA GRAVIS - MALAYSIA A CLINICAL SURVEY IN C.T. TAN T.G. LOH SUMMARY A retrospective study of 62 cases of myasthenia gravis in Malaysia is reviewed.
More informationamifampridine 10mg tablet, as phosphate (Firdapse ) BioMarin UK Ltd
amifampridine 10mg tablet, as phosphate (Firdapse ) BioMarin UK Ltd SMC No.(660/10) 06 July 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More informationThe Lambert-Eaton Myasthenic Syndrome an Overview
Review The Lambert-Eaton Myasthenic Syndrome an Overview Authors Siegfried Kohler, Andreas Meisel Affiliation Integrated Myasthenia Center, Department of Neurology, NeuroCure Clinical Research Center,
More informationLiving with. LEMS.com LAMBERT-EATON MYASTHENIC SYNDROME
PATIENT INFORMATION Living with LAMBERT-EATON MYASTHENIC SYNDROME You have received this leaflet as you have been diagnosed with Lambert-Eaton myasthenic syndrome, or LEMS. This leaflet will give you and
More informationNeuromuscular Junction Testing ELBA Y. GERENA MALDONADO, MD ACTING ASSISTANT PROFESSOR UNIVERSITY OF WASHINGTON MEDICAL CENTER
Neuromuscular Junction Testing ELBA Y. GERENA MALDONADO, MD ACTING ASSISTANT PROFESSOR UNIVERSITY OF WASHINGTON MEDICAL CENTER Objectives Neurophysiology Electrodiagnostic Evaluation Clinical Application
More informationClinical Study Headache Associated with Myasthenia Gravis: The Impact of Mild Ocular Symptoms
SAGE-Hindawi Access to Research Autoimmune Diseases Volume 2011, Article ID 840364, 4 pages doi:10.4061/2011/840364 Clinical Study Headache Associated with Myasthenia Gravis: The Impact of Mild Ocular
More informationREVIEW PRACTICAL NEUROLOGY. Pract Neurol: first published as /j x on 1 February Downloaded from
18 PRACTICAL EUROLOG REVIEW The managem myasthenia g Pract eurol: first published as 10.1111/j.1474-7766.2005.00280.x on 1 February 2005. Downloaded from http://pn.bmj.com/ David Hilton-Jones and Jackie
More informationThymectomy in myasthenia with pure ocular symptoms
Journal of Neurology, Neurosurgery, and Psychiatry 1985;48:332-337 Thymectomy in myasthenia with pure ocular symptoms F SCHUMM,* H WIETHOLTER.* A FATEH-MOGHADAM,t J DICHGANS* From the Department ofneurology,
More informationNIH Public Access Author Manuscript Lancet Neurol. Author manuscript; available in PMC 2009 August 24.
NIH Public Access Author Manuscript Published in final edited form as: Lancet Neurol. 2009 May ; 8(5): 475 490. doi:10.1016/s1474-4422(09)70063-8. Autoimmune myasthenia gravis: emerging clinical and biological
More informationHuman Physiology Lab (Biol 236L) Fall, 2015
1 Human Physiology Lab (Biol 236L) Fall, 2015 Name: Nursing Case Study: Muscle Weakness Chief Complaint: A 26-year-old woman with muscle weakness in the face. Patient Presentation: A 26-year-old woman
More informationSerologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I
Autoimmune Hepatitis By Thomas Frazier Objective What we need to know about AIH Diagnosis Treatment Difficulties in both Liver transplantation concerns AASLD Guidelines: Hepatology. 2010 Jun;51(6):2193-213.
More informationNEUROMUSCULAR BLOCKING AGENTS
NEUROMUSCULAR BLOCKING AGENTS Edward JN Ishac, Ph.D. Associate Professor, Pharmacology and Toxicology Smith 742, 828-2127, Email: eishac@vcu.edu Learning Objectives: 1. Understand the physiology of the
More informationreceptors determines clinical symptoms of the patients and modulates the sensitivity to nondepolarizing neuromuscular
346 Anesthesiology 2000; 93:346 50 2000 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Preanesthetic Train-of-four Fade Predicts the Atracurium Requirement of Myasthenia
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Soliris (eculizumab) Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Soliris (eculizumab) Prime Therapeutics will review Prior Authorization requests
More informationNeuromuscular Junction
Muscle Relaxants Neuromuscular Junction Cholinergic antagonists Neuromuscular-blocking agents (mostly nicotinic antagonists): interfere with transmission of efferent impulses to skeletal muscles. These
More informationNIH Public Access Author Manuscript Expert Rev Clin Immunol. Author manuscript; available in PMC 2013 May 01.
NIH Public Access Author Manuscript Published in final edited form as: Expert Rev Clin Immunol. 2012 July ; 8(5): 427 438. doi:10.1586/eci.12.34. Muscle autoantibodies in myasthenia gravis: beyond diagnosis?
More informationClinical Commissioning Policy Proposition:
Clinical Commissioning Policy Proposition: Rituximab for the treatment of dermatomyositis and polymyositis (Adults) Reference: NHS England A13X05/01 Information Reader Box (IRB) to be inserted on inside
More informationRunning head: SUGAMMADEX AND MYASTHENIA GRAVIS 1
Running head: SUGAMMADEX AND MYASTHENIA GRAVIS 1 Sugammadex in Patients with Myasthenia Gravis Jennifer A. Madsen University of Kansas SUGAMMADEX AND MYASTHENIA GRAVIS 2 Title of Proposed Research Project
More informationNeuroimmunology. Innervation of lymphoid organs. Neurotransmitters. Neuroendocrine hormones. Cytokines. Autoimmunity
Neuroimmunology Innervation of lymphoid organs Neurotransmitters Neuroendocrine hormones Cytokines Autoimmunity CNS has two ways of contacting and regulating structures in the periphery Autonomic
More informationMyasthenia Gravis and Lambert-Eaton Myasthenic Syndrome Michael W. Nicolle, MD
Review Article Downloaded from https://journals.lww.com/continuum by maxwo3znzwrcfjddvmduzvysskax4mzb8eymgwvspgpjoz9l+mqfwgfuplwvy+jmyqlpqmifewtrhxj7jpeo+505hdqh14pdzv4lwky42mcrzqckilw0d1o4yvrwmuvvhuyo4rrbviuuwr5dqytbtk/icsrdbt0hfryk7+zagvaltkgnudxdohhaxffu/7kno26hifzu/+bcy16w7w1bdw==
More informationCURRENT MEDICINE MYASTHENIA GRAVIS
MYASTHENIA GRAVIS M.E. Farrugia, Specialist Registrar in Neurology, and R.J. Swingler, Consultant Neurologist, Department of Neurology, Ninewells Hospital and Medical School, Dundee SUMMARY Myasthenia
More informationPatient: RG DOB: NKDA
Patient: RG DOB: 09.26.1959 NKDA RG presented to the ED complaining of new onset generalized weakness Difficulty walking, fatigued with exertion, feeling off balance, dry mouth, and dysphasia HPI: approximately
More informationChemistry 106: Drugs in Society Lecture 16: An Introduction to the Modern View of Drug Effect 5/04/18
Chemistry 106: Drugs in Society Lecture 16: An Introduction to the Modern View of Drug Effect 5/04/18 By the end of this session, you should be able to 1. Develop a sense of scale between the individual
More informationRepetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis
JCN Open Access pissn 1738-6586 / eissn 2005-5013 / J Clin Neurol 2017 ORIGINAL ARTICLE Repetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis Seung Woo Kim a * Mun Kyung Sunwoo b * Seung
More informationAssessment Instruments for Your Patients with Myasthenia Gravis (MG)
Assessment Instruments for Your Patients with Myasthenia Gravis (MG) Table of Contents Reported by patient Myasthenia Gravis Activities of Daily Living (MG-ADL): ~10 minutes 8-item outcome measure that
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationCitation Hong Kong Practitioner, 2000, v. 22 n. 1, p. 8-20
Title An update on myasthenia gravis Author(s) Chan, KH; Ho, SL Citation Hong Kong Practitioner, 2000, v. 22 n. 1, p. 8-20 Issued Date 2000 URL http://hdl.handle.net/10722/45090 Rights This work is licensed
More informationBasics of Pharmacology
Basics of Pharmacology Pekka Rauhala Transmed 2013 What is pharmacology? Pharmacology may be defined as the study of the effects of drugs on the function of living systems Pharmacodynamics The mechanism(s)
More informationAnesthetic management of a patient with Myasthenia Gravis for abdominal surgery.
The Greek E-Journal of Perioperative Medicine 2017; 16(c): 47-54 (ISSN 1109-6888) www.e-journal.gr/ Ελληνικό Περιοδικό Περιεγχειρητικής Ιατρικής 2017; 16(c): 47-54 (ISSN 1109-6888) www.e-journal.gr/ 47
More informationAn autoimmune perspective on neuromuscular diseases
An autoimmune perspective on neuromuscular diseases Colin Chalk MD,CM FRCPC Montreal General Hospital McGill University Schlomchik 2001 The proportion of neuromuscular patients who have an autoimmune cause
More informationChapter 18 Neuromuscular Blocking Agents Study Guide and Application Exercise
Chapter 18 Neuromuscular Blocking Agents Study Guide and Application Exercise 1. Read chapter 2. Review objectives (p.305) 3. Review key terms and definitions (p.305) Add: Cholinesterase inhibitor Vagal
More informationSymptomatic pain treatments (carbamazepine and gabapentin) were tried and had only a transient and incomplete effect on the severe pain syndrome.
Laurencin 1 Appendix e-1 Supplementary Material: Clinical observations Patient 1 (48-year-old man) This patient, who was without a notable medical history, presented with thoracic pain and cough, which
More informationJMSCR Vol 05 Issue 04 Page April 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i4.65 Clinical-Immunological Profile of Myasthenia
More informationAUTOIMMUNE DISORDERS IN THE ACUTE SETTING
AUTOIMMUNE DISORDERS IN THE ACUTE SETTING Diagnosis and Treatment Goals Aimee Borazanci, MD BNI Neuroimmunology Objectives Give an update on the causes for admission, clinical features, and outcomes of
More informationM yasthenia gravis is a potentially serious
690 REVIEW Update on myasthenia gravis B R Thanvi, T C N Lo... Myasthenia gravis is an autoimmune disorder caused by autoantibodies against the nicotinic acetylcholine receptor on the postsynaptic membrane
More informationSigns: The most common sign seen by ophthalmologists are lid droop
Myasthenia Gravis Your doctor thinks that you have Myasthenia Gravis (MG). This is an autoimmune condition where the body's immune system has damaged receptors on your muscles. This results in muscle weakness
More informationDiagnosis and management of myasthenia gravis
Diagnosis and management of myasthenia gravis Sivakumar Sathasivam MRCP (UK), LLM, PhD Myasthenia gravis is the most common primary disorder of neuromuscular transmission and one of the most treatable
More informationTHYMECTOMY. Thymectomy. Common questions patients ask about thymectomies.
THYMECTOMY Thymectomy Common questions patients ask about thymectomies. www.myasthenia.org mectomy 8pages.indd 1 The following are some of the most common questions asked when a thymectomy is being considered
More informationPROSTIGMIN (neostigmine bromide)
PROSTIGMIN (neostigmine bromide) TABLETS DESCRIPTION: Prostigmin (neostigmine bromide), an anticholinesterase agent, is available for oral administration in 15 mg tablets. Each tablet also contains gelatin,
More informationNeurology. Brain death. Tests. EEG in Monitoring 3.B.2. Neuromuscular disorders and anaesthesia. Neurology 3.C.6.1 James Mitchell (December 24, 2003)
Neurology Brain death Tests EEG in Monitoring 3.B.2 Neuromuscular disorders and anaesthesia Neurology 3.C.6.1 James Mitchell (December 24, 2003) Brain death Coma GCS < 8, potential for recovery Persistent
More informationClinical predictors for the prognosis of myasthenia gravis
Wang et al. BMC Neurology (2017) 17:77 DOI 10.1186/s12883-017-0857-7 RESEARCH ARTICLE Open Access Clinical predictors for the prognosis of myasthenia gravis Lili Wang *, Yun Zhang and Maolin He Abstract
More informationMedicine, University of Lund, Sweden
336 J. Phy8iol. (1961), 156, pp. 336-343 With 6 text-ftgures Printed in Great Britain AN ELECTROPHYSIOLOGIC STUDY OF THE NEURO- MUSCULAR JUNCTION IN MYASTHENIA GRAVIS BY 0. DAHLBACK, D. ELMQVIST, T. R.
More informationThymectomy (Removal of the Thymus)
Information about Thymectomy (Removal of the Thymus) This leaflet will give you information about Thymectomy which is a surgical procedure to remove the thymus. Department of Neurology Queen Elizabeth
More informationVideo-assisted thymectomy for myasthenia gravis: an update of a single institution experience q
European Journal of Cardio-thoracic Surgery 22 (2002) 978 983 www.elsevier.com/locate/ejcts Abstract Video-assisted thymectomy for myasthenia gravis: an update of a single institution experience q Michal
More informationMajor Review Ocular Myasthenia. Historical Perspective. Physiology of Neuromuscular Transmission. Natural history
Major Review Ocular Myasthenia Ann J K DO,DNB, FAICO (Oculoplasty), Ani Sreedhar MS Myasthenia gravis is a chronic neuromuscular disorder, characterized by weakness and fatiguability of voluntary muscles.
More informationFirst described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"
Parkinson's Disease First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy" Parkinson s disease (PD) is a neurological disorder characterized by a progressive
More informationDrugs Affecting the Autonomic Nervous System-2 Cholinergic agents
Drugs Affecting the Autonomic Nervous System-2 Cholinergic agents Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Cholinergic agents, Cholinomimetic drugs,
More information42 y/o woman with unwitnessed episode of loss of consciousness and urinary incontinence
Top Five Neurological Emergencies: When To Refer February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation 1 CASE 1 42 y/o woman with unwitnessed episode
More informationA Case of Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated With Outpatient Periodic Weekly Blood Purification Therapy
doi: 10.2169/internalmedicine.9466-17 Intern Med Advance Publication http://internmed.jp CASE REPORT A Case of Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated With Outpatient Periodic
More informationEffectiveness of immunotherapy in myasthenia gravis: Epidemiological evidence from Sri Lanka
Neurology Asia 2005; 10 : 39 45 Effectiveness of immunotherapy in myasthenia gravis: Epidemiological evidence from Sri Lanka Padma S GUNARATNE FRCP FCCP, *Hanna A LARSEN, **Amita K MANATUNGA PhD Teaching
More informationDrug Class Prior Authorization Criteria Immune Globulins
Drug Class Prior Authorization Criteria Immune Globulins Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy has been developed through review of
More information2014 Japanese Society for Neuroim
NAOSITE: Nagasaki University's Ac Title Author(s) Citation Clinical features and treatment sta Murai, Hiroyuki; Masuda, Masayuki; Yuriko; Suzuki, Shigeaki; Imai, Tom Shingo; Kira, Jun-ichi Clinical and
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More informationPharmacology of the Neuromuscular Junction (NMJ)
Pharmacology of the Neuromuscular Junction (NMJ) Edward JN Ishac, Ph.D. Professor Smith Building, Room 742 eishac@vcu.edu 828 2127 Department of Pharmacology and Toxicology Medical College of Virginia
More information5.1 Alex.
5.1 Alex http://tinyurl.com/neuromakessense Alex is a 20-year-old full-time national serviceman. His only past medical history is asthma, presents to A&E with a 4-day history of bilateral finger weakness
More informationMycophenolate mofetil (MMF) for Myasthenia
Neurology and Pharmacy directorate Mycophenolate mofetil (MMF) for Myasthenia Introduction This leaflet provides information on a medicine called mycophenolate mofetil (MMF) when it is used to treat myasthenia
More informationPlasma exchange and immunosuppressive drug
Journal of Neurology, Neurosurgery, and Psychiatry, 1981, 44, 469-475 Plasma exchange and immunosuppressive drug treatment in myasthenia gravis: no evidence for synergy C H R I ST OPHER J HAWKEY, JOHN
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationPRIMARY DISEASES OF MYELIN. By: Shifaa Al Qa qa
PRIMARY DISEASES OF MYELIN By: Shifaa Al Qa qa Most diseases of myelin are primarily white matter disorders??? Myelinated axons most diseases of CNS myelin do not involve the peripheral nerves to any significant
More information